[Federal Register Volume 70, Number 134 (Thursday, July 14, 2005)]
[Notices]
[Page 40689]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 05-13856]


=======================================================================
-----------------------------------------------------------------------

DEPARTMENT OF DEFENSE

Department of the Army


Availability for Non-Exclusive, Exclusive, or Partially Exclusive 
Licensing of U.S. Provisional Patent Applications Concerning Inhibitors 
of Type F Botulinum Neurotoxin Proteinase Activity

AGENCY: Department of the Army, DoD.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: In accordance with 37 CFR 404.6 and 404.7, announcement is 
made of the availability for licensing of the invention set forth in 
U.S. Provisional Patent Application Serial No. 60/656,551 entitled 
``Inhibitors of Type F Botulinum Neurotoxin Proteinase Activity,'' 
filed February 17, 2005; as well as the invention set forth in related 
U.S. Provisional Patent application Serial No. 60/660,024 entitled 
``Inhibitors of Type F Botulinum Neurotoxin Proteinase Activity,'' 
filed February 23, 2005. The United States Government, as represented 
by the Secretary of the Army, has rights in this invention.

ADDRESSES: Commander, U.S. Army Medical Research and Materiel Command, 
ATTN: Command Judge Advocate, MCMR-ZA-J, 504 Scott Street, Fort 
Detrick, Frederick, MD 21702-5012.

FOR FURTHER INFORMATION CONTACT: For patent issues, Ms. Elizabeth 
Arwine, Patent Attorney, (301) 619-7808. For licensing issues, Dr. Paul 
Mele, Office of Research & Technology Assessment, (301) 619-6664, both 
at telefax (301) 619-5034.

SUPPLEMENTARY INFORMATION: Botulinum neurotoxins (BoNTs A-G) are zinc 
metalloendoproteases that exhibit extraordinary specificities for 
proteins involved in neurotransmitter release. In view of the extreme 
toxicities of these molecules, their applications in human medicine, 
and potential for misuse, it is of considerable importance to elucidate 
the mechanisms underlying substrate recognition and to develop 
inhibitors, with the ultimate goal of obtaining anti-botulinum drugs.

Brenda S. Bowen,
Army Federal Register Liaison Officer.
[FR Doc. 05-13856 Filed 7-13-05; 8:45 am]
BILLING CODE 3710-08-M